138 related articles for article (PubMed ID: 38103177)
1. Reducing cardiovascular outcomes with semaglutide: a metabolic route for a SELECT few.
Liuzzo G; Patrono C
Eur Heart J; 2024 Feb; 45(8):570-571. PubMed ID: 38103177
[No Abstract] [Full Text] [Related]
2. Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials.
Mellbin LG; Bhatt DL; David JP; Ekström K; Petrie MC; Rasmussen S; Vilsbøll T
Eur Heart J; 2024 Apr; 45(15):1371-1374. PubMed ID: 38416593
[No Abstract] [Full Text] [Related]
3. Comment on: Semaglutide and cardiovascular outcomes in obesity without diabetes.
Basolo A; Fierabracci P; Salvetti G; Santini F
J Endocrinol Invest; 2024 May; 47(5):1047-1049. PubMed ID: 38157134
[No Abstract] [Full Text] [Related]
4. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I
Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985
[TBL] [Abstract][Full Text] [Related]
5. Once-Weekly Semaglutide Is an Effective Adjunct for Weight Loss in Adults without Diabetes Who Are Overweight or Obese.
Slawson DC
Am Fam Physician; 2021 Jul; 104(1):96-97. PubMed ID: 34264618
[No Abstract] [Full Text] [Related]
6. Oral semaglutide in Japanese versus non-Japanese patients with type 2 diabetes.
Scheen AJ
Lancet Diabetes Endocrinol; 2020 May; 8(5):350-352. PubMed ID: 32333865
[No Abstract] [Full Text] [Related]
7. Switching from subcutaneous to oral semaglutide in type 2 diabetes: A prospective study.
Martínez-Montoro JI; Picón-César MJ; Generoso-Piñar M; Fernández-Valero A; López-Montalbán Á; Simón-Frapolli VJ; Hernández-Bayo J; Pinzón-Martín JL; Tinahones FJ
J Intern Med; 2024 Jan; 295(1):113-115. PubMed ID: 37902577
[No Abstract] [Full Text] [Related]
8. [The glucagon-like peptide-1 receptor-agonist semaglutide].
Boje AD; Juhl CR; Torekov SS; Madsbad S
Ugeskr Laeger; 2019 Oct; 181(41):. PubMed ID: 31610830
[TBL] [Abstract][Full Text] [Related]
9. Semaglutide Associated With Less Insulin Need in Early Type 1 Diabetes.
Harris E
JAMA; 2023 Oct; 330(14):1318. PubMed ID: 37728959
[No Abstract] [Full Text] [Related]
10. Semaglutide reduces the absolute risk of major cardiovascular events by 1.5.
Phizackerley D
BMJ; 2024 Jan; 384():q53. PubMed ID: 38224977
[No Abstract] [Full Text] [Related]
11. Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?
Doggrell SA
Expert Opin Biol Ther; 2020 May; 20(5):489-492. PubMed ID: 32005073
[No Abstract] [Full Text] [Related]
12. Oral semaglutide (Rybelsus) for type 2 diabetes.
Med Lett Drugs Ther; 2019 Oct; 61(1583):166-168. PubMed ID: 31770356
[No Abstract] [Full Text] [Related]
13. Semaglutide Improved Cardiovascular Health in People Without Diabetes.
Harris E
JAMA; 2023 Dec; 330(23):2241-2242. PubMed ID: 38019508
[No Abstract] [Full Text] [Related]
14. Safety of Semaglutide.
Smits MM; Van Raalte DH
Front Endocrinol (Lausanne); 2021; 12():645563. PubMed ID: 34305810
[TBL] [Abstract][Full Text] [Related]
15. Oral Semaglutide (Rybelsus) for the Treatment of Type 2 Diabetes Mellitus.
Semenya AM; Wilson SA
Am Fam Physician; 2020 Nov; 102(10):627-628. PubMed ID: 33179892
[No Abstract] [Full Text] [Related]
16. Semaglutide Is a New Once-Daily Oral Medication to Treat Type 2 Diabetes.
Blakely KK; Weaver K
Nurs Womens Health; 2020 Oct; 24(5):370-376. PubMed ID: 32890462
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.
Tan X; Cao X; Zhou M; Zou P; Hu J
Expert Opin Investig Drugs; 2017 Sep; 26(9):1083-1089. PubMed ID: 28741970
[TBL] [Abstract][Full Text] [Related]
18. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
Cowart K
Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
[No Abstract] [Full Text] [Related]
19. Efficacy of semaglutide versus liraglutide in clinical practice.
Goncalves E; Bell DS
Diabetes Metab; 2020 Nov; 46(6):515-517. PubMed ID: 31606525
[No Abstract] [Full Text] [Related]
20. Oral glucagon-like peptide-receptor agonists (GLP1RA) counseling: comparison with insulin counseling.
Kalra S; Kalhan A; Berard L
Postgrad Med; 2020 Nov; 132(8):663-666. PubMed ID: 32781867
[No Abstract] [Full Text] [Related]
[Next] [New Search]